A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis

被引：0
作者：
Ahmadreza Jamshidi
Farhad Gharibdoost
Mahdi Vojdanian
Soosan G. Soroosh
Mohsen Soroush
Arman Ahmadzadeh
Mohammad Ali Nazarinia
Mohammad Mousavi
Hadi Karimzadeh
Mohammad Reza Shakibi
Zahra Rezaieyazdi
Maryam Sahebari
Asghar Hajiabbasi
Ali Asghar Ebrahimi
Najmeh Mahjourian
Amin Mohammadinejad Rashti
机构：
[1] Rheumatology Research Center,Department of Rheumatology
[2] Tehran University of Medical Sciences,Department of Rheumatology
[3] AJA university of Medical Sciences Rheumatology research center,Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences
[4] AJA university of Medical Sciences Internal medicine,Rheumatic Diseases Research Center, Faculty of Medicine
[5] Rheumatology Section,Guilan Rheumatology Research Center, Department of Rheumatology, Razi Hospital, School of Medicine
[6] Loghman e Hakim Hospital,undefined
[7] Shahid Beheshti University of Medical Sciences,undefined
[8] Shiraz Geriatric Research Center,undefined
[9] Shiraz University of Medical Sciences,undefined
[10] Department of Rheumatology,undefined
[11] School of Medicine,undefined
[12] Shahrekord University of Medical Sciences,undefined
[13] Shahrekord AND Behcet’s Unit,undefined
[14] Rheumatology Research Center,undefined
[15] Tehran University of Medical Sciences,undefined
[16] Al-Zahra Hospital,undefined
[17] Kerman University of Medical Sciences,undefined
[18] Mashhad University of medical Sciences,undefined
[19] Guilan University of Medical Sciences,undefined
[20] Tabriz University of Medical Sciences,undefined
[21] Connective Tissue Reserch Center,undefined
[22] Tehran University of Medical Sciences,undefined
[23] Tehran University of Medical Sciences,undefined
[24] Faculty of Pharmacy,undefined
来源：
Arthritis Research & Therapy | / 19卷
关键词：
Adalimumab; Biosimilar; CinnoRA®; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 117 条
  • [11] Van Tuyl LH(2001)Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 907-16
  • [12] Funovits J(2004)Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Ann Rheum Dis 63 508-7
  • [13] Mota LMH(2015)Biosimilars in rheumatology: what the clinician should know RMD open 1 e000010-81
  • [14] Cruz BA(2014)Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies Joint Bone Spine 81 471-35
  • [15] Brenol CV(2010)2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Arthritis Rheum 62 2569-45
  • [16] Pereira IA(1995)American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 727-98
  • [17] Rezende-Fronza LS(1980)Measurement of patient outcome in arthritis Arthritis Rheum 23 137-9
  • [18] Bertolo MB(2002)A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis J Rheumatol 29 2288-7
  • [19] Smolen JS(2011)Statistical considerations for confirmatory clinical trials for similar biotherapeutic products Biologicals 39 266-9
  • [20] Landewé R(2011)Biosimilars clinical development program: confirmatory clinical trials: a virtual/simulated case study comparing equivalence and non-inferiority approaches Biologicals 39 270-ii6
12345678910